Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label genotypes;All. Show all posts
Showing posts with label genotypes;All. Show all posts
Tuesday, February 26, 2019

Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification

›
Open Forum Infectious Diseases https://doi.org/10.1093/ofid/ofz076 Published: 22 February 2019  Accepted Manuscript Identificati...
Thursday, February 21, 2019

Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy

›
Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy Arnolfo Petruzziello , Rocco Sabatino, Giovanna Loq...
Saturday, February 9, 2019

Mavyret - Safety and efficacy in patients receiving opioid substitution therapy/HCV genotypes 1-6

›
Int J Drug Policy. 2019 Feb 5;66:73-79. doi: 10.1016/j.drugpo.2019.01.011. [Epub ahead of print] Safety and efficacy of glecaprevir/pib...
Tuesday, December 4, 2018

China's National Medical Products Administration Approves Harvoni®

›
China’s National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genot...
Saturday, November 3, 2018

Minireview - Era of direct acting anti-viral agents for the treatment of hepatitis C

›
World J Hepatol. Oct 27, 2018; 10(10): 670-684 Published online Oct 27, 2018. doi: 10.4254/wjh.v10.i10.670 The different DAAs with thei...

New highly diverse hepatitis C strains detected in sub‐Saharan Africa have unknown susceptibility to direct‐acting antiviral treatments

›
New highly diverse hepatitis C strains detected in sub‐Saharan Africa have unknown susceptibility to direct‐acting antiviral treatments  Ch...
Thursday, September 20, 2018

Ultra-Short Treatment of Hepatitis C - Cocrystal Pharma Completes Patient Enrollment in Phase 2a Study Evaluating CC-31244

›
ATLANTA, GA and BOTHELL, WA, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a cl...
Wednesday, June 13, 2018

High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis

›
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis ...
Tuesday, June 12, 2018

Blogger Updates: Opioid & hepatitis C epidemic

›
Thanks for stopping by, we begin with an article about the opioid & hepatitis C epidemic, published today online over at Harvard Law...
Saturday, June 2, 2018

Weekend Reading: When to Initiate HCV Therapy and Overview Of New Drugs

›
If you landed here this weekend looking for information about treating the hepatitis C virus (HCV), you're in luck! Sit back, gra...
Friday, April 13, 2018

First real-world data on Mavyret showing safety & effectiveness in HCV Genotype 1-6

›
Shared on Twitter today by @HenryEChang - First real-world data from the Deutsches Hepatitis C-Register (DHC-R) showing favorable safety ...
Saturday, December 2, 2017

Mavyret: A Pan-Genotypic Combination Therapy for the Treatment of Hepatitis C Infection

›
Published as part of the Biochemistry series “Biochemistry to Bedside” Department of Biochemistry and Molecular Pharmacology, University of...
Saturday, November 25, 2017

Drug resistance-associated substitutions identified in HCV genes

›
Gastroenterology 2017 View Abstract In Press: Patterns of Resistance-associated Substitutions in Patients With Chronic HCV Infection Fo...
Tuesday, October 17, 2017

The changing HCV treatment cascade

›
Healio HCV Next Pharmacology Consult The changing HCV treatment cascade Infectious Disease News, October 2017 Jocelyn Mason, PharmD; K...
Wednesday, September 27, 2017

Japan - AbbVie Announces Approval of MAVIRET™ (glecaprevir/pibrentasvir) of Chronic Hepatitis C in All Major Genotypes (GT1-6)

›
AbbVie Announces Approval of MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in...
Tuesday, September 26, 2017

Hepatitis C cross-genotype immunity and implications for vaccine development

›
Hepatitis C cross-genotype immunity and implications for vaccine development Nazrul Islam, Mel Krajden, Jean Shoveller, Paul Gustafson, Ma...
Monday, September 25, 2017

Gilead's Sovaldi® (Sofosbuvir) Approved In China for Treatment of Chronic Hepatitis C

›
China Food and Drug Administration Approves Gilead's Sovaldi® (Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Infection - Sov...
Saturday, August 26, 2017

The new paradigm in the treatment of chronic hepatitis C disease: Faster, Higher and Stronger

›
Citius Altius Fortius: The new paradigm in the treatment of chronic hepatitis C disease George M Abraham, MD, MPH   ...
Thursday, August 17, 2017

AbbVie's MAVIRET Approved by Health Canada

›
AbbVie's MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes MAVIRET is the first a...
Friday, July 21, 2017

BVHG/BASL/BSG/BHIVA/BIA/CVN Guidelines for management of chronic HCV infection

›
HCV consensus treatment guidelines BVHG/BASL/BSG/BHIVA/BIA/CVN Guidelines for management of chronic HCV infection Download PDF Prefac...